ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,345 GBX | +0.66% |
|
+1.51% | +16.42% |
| 05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
| 05-08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 51.34B 70.29B | Sales 2025 * | 55.01B 75.32B | Capitalization | 238B 325B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.62B 11.8B | Net income 2025 * | 10.29B 14.09B | EV / Sales 2024 * | 5.03 x |
| Net Debt 2024 * | 20.53B 28.12B | Net Debt 2025 * | 13.65B 18.69B | EV / Sales 2025 * | 4.57 x |
| P/E ratio 2024 * |
28
x | P/E ratio 2025 * |
23.3
x | Employees | 89,900 |
| Yield 2024 * |
2% | Yield 2025 * |
2.11% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | +0.65% | ||
| 1 week | +1.51% | ||
| Current month | +2.30% | ||
| 1 month | +15.24% | ||
| 3 months | +26.42% | ||
| 6 months | +18.24% | ||
| Current year | +16.42% |
1 week
11 966.00
12 388.00
1 month
10 618.0012 488.00
Current year
9 461.0012 488.00
1 year
9 461.0012 488.00
3 years
7 556.0012 488.00
5 years
5 642.0012 488.00
10 years
3 680.0012 488.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 0 M€ | +15.90% | ||
| 5.17% | 0 M€ | +5.54% | - | |
| 4.89% | 0 M€ | +11.41% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 12,344 | +0.65% | 317 156 |
| 24-05-08 | 12,264 | +1.20% | 2,091,841 |
| 24-05-07 | 12,118 | +0.56% | 2,562,233 |
| 24-05-03 | 12,050 | -0.87% | 1,642,783 |
| 24-05-02 | 12,156 | -0.12% | 2,006,478 |
Delayed Quote London S.E., May 09, 2024 at 10:51 am
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
153.2
USD
Average target price
166.5
USD
Spread / Average Target
+8.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.42% | 238B | |
| +33.07% | 698B | |
| +26.51% | 568B | |
| -4.33% | 358B | |
| +19.17% | 328B | |
| +3.97% | 283B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +7.62% | 165B | |
| -3.87% | 160B |
- Stock Market
- Equities
- AZN Stock